HealthSens S.L. is a “Spin-off” of the Hospital Universitario Central de Asturias and the University of Oviedo set up with the objective of developing, producing and commercializing electrochemical sensors to be used in the detection of biomarkers in highly prevalent diseases, thus enabling early diagnosis and/or appropriate follow-up of patients.
Healthsens specializes in the development of Point of Care (POCT) medical devices for the diagnosis and monitoring of high-impact pathologies in our society, including oncological (prostate cancer), neurodegenerative (Alzheimer’s), renal (chronic kidney disease) and digestive (celiac disease) diseases. The devices developed by Healthsens are easy to use, non-invasive, compact and portable so they can be used by non-specialized personnel outside laboratories, for example in Primary Care Centers, pharmacies and doctor’s consultation rooms. In some cases, the devices could be used by the patient at their home (e.g. the medical device for monitoring kidney disease). Healthsens is also aiming to develop a system for the treatment of Alzheimer’s disease based on the immunological capture of amyloid peptides in the cerebrospinal fluid.
Our vision is aligned with current health trends, focusing on a better patient management and higher quality of care, thus contributing to the personalization of healthcare practice and the sustainability of the health system.
Solving worldwide health and wellness needs
Mangrana is a highly scalable eHealth technology platform that uses multidisciplinary and artificial professional intelligence to empower and educate citizens around the world, regardless of their socioeconomic and cultural background, about when and what decisions to make regarding their basic health and wellness.
Currently access to education and basic advice on the most frequent health problems facing the world citizens, is not available to the entire population, however smartphone users are accounted for billions and people who consult the internet (websites and apps) In front of their symptoms are approaching this year to 700 million.
Mangrana’s first product, “wtswrng” is a smartphone app that helps citizens to make decisions about when and what health resources to use. It is the first symptom checker that can be used globally and by all types of citizens who have a smartphone, since it uses the universal language of images.
The global data captured regarding the patterns of symptoms as well as the behaviors of the people in relation to their basic health needs, will be of great epidemiological, sociological and commercial value.
The Idiopathic Pulmonary Fibrosis produces scarring of lung tissue decreasing progressively the breath autonomy of the patient. IPF is a serious disease that usually affects middle-aged and older adults. Many people live only about 3 to 5 years after diagnosis. 3 million of patients around the world are estimated to have IPF. Without it is impossible to know the actual number since it is often misdiagnosed as different pathologies with similar symptoms.
To improve its detection, in eKuore we are working with Boehringer-Ingelheim (BI) in the development of an IPF early detection system.
In this way, eKuore will develop the devices able to register the auscultation and upload them to the Cloud where them will be compared with identified patterns of FPI by the algorithm designed by BI. This will give an early diagnose of the disease and will refer the patient to the specialist.
Aulas Mindfulness have the mission of spreading the benefits of mindfulness to the greatest number of people and collaborate in building a better educational, business and social environment, offering schools, companies, professionals and individuals customized solutions adapted to their needs In a changing scenario, through talks, courses and workshops of mindfulness that allow to experience and connect with mindfulness.
The training activity of Aulas Mindfulness focuses on the following programs:
• Mindfulness in schools.
• Mindfulness for parents.
• Mindfulness in companies.
• Mindfulness in open for individuals (initiation and deepening).
We want to contribute to generate a movement that encourages the adoption of healthier life habits: better management of stress, greater control of the swing of emotions, knowing how to respond and not react … All this reverts to the benefit of each individual And in the one of their environment creating a more conscious, more attentive society, with more empathy. We seek that each of the people who come to our formations integrate them in their day to day and that generates a state of calm and clarity even in the difficult moments. This way of being present gives a new perspective to life.
We have been accredited as MBCT (Mindfulness based Cognitive Therapy) Center for Mindfulness Research and Practice (CMRP) of the University of Bangor (UK), following the “Evaluation criteria of teaching interventions based on Mindfulness” Based interventions: Teaching Assessment Criteria – MBI-TAC). These criteria have been developed by CMRP instructors from the University of Bangor in collaboration with the Universities of Exeter and Oxford.
Knowledgeable and with much experience in the sector of animal companionship, our Project is to open a new chain of establishments in this sector dedicated to these distinct activities: veterinary consultants, canine and feline beauty shops, spa, recovery center for dogs with mobility problems, etc. and pet stores.
Our establishments, with store designs that are novel and attractive, get away from the traditional store; they will be situated in the best, most important, most prestigious commercial centers of the country, El Corte Ingles.
In this moment the sector of animal companionship is growing in Spain at the level of other European countries that have already developed it years before. Companies, dedicated to the pet sector, are being bought by foreign investors and being placed in established commercial places that have stores in distinct parts of the country.
Developing these types of stores in large commercial chains of Spain, like El Corte Ingles, will situate us in a good position of having the possibility of opening 70 stores in all of Spain. We have assured traffic, that is, El Corte´s clientele, in addition customers that already have pets and want to find out what offers we have as an external operator operating within El Corte Ingles, but still offer the same guarantees.
The project can have one service or various depending on the size and characteristics of the center.
DESCRIPTION OF THE BUSINESS
Presentation of the Company:
Bioprognos is a biotech company, created in January 2016 and dedicated to the development of diagnostic solutions for the early detection of different types of cancer through a simple blood test.
To improve clinical outcomes and quality of life for cancer, by developing innovative, non-invasive, accurate, and cost-effective diagnostics solutions.
To be the top reference worldwide diagnostics company that allow people to enjoy better health.
TECHNOLOGY – ADVANTAGES OF THE PRODUCT / SERVICE
The test “MBDAA for Lung Neoplasia Dx”, calculates the risk of lung cancer ―and provides histology in the case of a positive test―, combining the values of 6 tumour markers obtained with a simple blood test, with other clinical data from the patient, with a 93,5% Sensitivity and 96.2% Specificity.
DISTRIBUTION AND MARKETING
Our coverage model will be Direct and Indirect Sales, in a world wide market.
Public and Private Authorities involved in cancer prevention protocols
Clinical Analysis Laboratories (Private and Public) with, or no experience with tumor biomarkers
Institutes of Oncology
PARTNERSHIPS / COOPERATION AGREEMENTS
In a couple of weeks we are starting a multi country proof of concept project with an International and relevant laboratorie. NDA signed.
EXPECTED LEVEL OF COMPETITION AND COMPETITORS
Our main competitor for Lung cancer might be the test known as PAULA.
MAIN MILESTONES ACHIEVED SO FAR
We have reached the “CE Declaration of Conformity” (CE Mark) for our Lung Cancer MBDAA Algorithm.
1 Algorithm ready to Market this month
2 Algorithms expected ready to Market in 3 months
STRATEGIC DEVELOPMENT TARGETS
Improve the Especificity and Sensibility for 12 new Cancer Algorithms, starting from Lung cancer and reduce the Go-to-Market time frame
MediCheck is the solution for access to prívate healthcare in an affordable way, without needing to pay fixed monthly fees.
In analyzing the private healthcare sector, we identified a series of barriers to access for part of the population. MediCheck puts clinics in contact with patients through the web and the MediCheck app in order to create the best healthcare market where supply and demand is found at equilibrium prices in which both parties benefit. We put in place quick and quality healthcare with prices that are accessible to patients and fair to professionals.
We are a multi-discipline team with potential, motivation, and the necessary experience, both in the healthcare realm and the business environment, to establish this project as a real alternative to health insurance. Today we have fully developed the technology as well as an ample medical team, which allows us to direct all our resources toward the business growth of the project.
Bioquochem S.L. is a biotechnology company dedicated to the development of products and devices for measuring biomarkers in health and food BIOPARAMETERS.
In the early days of the company, our “target” focuses on R & D groups in universities, hospitals or different companies. However, our most ambitious goal is to bring these products to the target audience predictive or diagnostic purposes (in the case of diseases or sport).
Bioquochem has two distinct business lines:
A) Portable devices for measuring biomarkers. This business line has three distinct areas:
1. Health: Devices for early detection of diseases such as brain stroke or cancer. It is in this section
that we are currently focusing our efforts and for which the investment is requested.
It is our most ambitious aim is the development of a portable device for the assessment of cardiovascular
risk in early stages, the use of which will go to hospitals, intensive care units or outpatient clinics.
2. Sport: Devices for measuring the resilience of athletes after strenuous physical exertion. This measure
is designed to prevent episodes of overtraining.
3. Food: Devices for assessing various parameters of food quality.
B) Biological Kits for use in laboratories globally.
T BIOM. BIOTECH R&D
In Europe and USA there is from 70 to 100M of people affected by sleep apnea (SAHS) that makes
around 1520% of the total population. 20% of these affected persons are diagnosed by specialists and use a conventional CPAP. Around 58% (1,6M) of these patients need to travel often, due to work or for leisure, and can’t use a CPAP that is truly portable on means of transportation such as planes or where there is no power source, etc.
For this reason we have created POCPAP, a portable and autonomous air impulsion device to supply assisted air circulation in the treatment of sleep apnea syndrome (people affected by SAHS) and to improve sleep on high performance and elite athletes. CPAP features are autonomy, portability, adaptability, suitability for use “off the grid”, noise reduction, and other aspects. POCPAP is easy to detach, clean and, at the same time, it has sensors that allow to obtain important parameters of the patients, such as temperature, breath and heart rate, ECG registry and other data that the specialist considers useful and that can be sent through a smartphone.
We would like to emphasise that our patent includes a particular air flow and control servo system that allows to greatly reduce the energy cost dedicated to keep the air pressure on the soft palate, opening possibilities for pulmonologists like the gradual reeducation of this body part.
We require a capital of 205.000€ from external investors from a total of 1.100.000€ to start with the industrial serialization of the product, clinical assays and marketing. With these funds we expect to get benefits of 5.851.000€ after taxes in a period of 6 years.
BRUCELLA GREEN VAC
The only effective solution to solve the interference problem in the diagnosis of brucellosis.
Achievable market: 2,300,000 cattle (sheep and cattle). We manufacture in CZV (Porriño, Spain) modified vaccines based on the classical effective vaccines S19 and Rev-1 (the latter in a second phase) that have a florescent protein of marine origin (GFP – Green Fluor Protein) as a biological marker, and are going on to create the new S19-GFP and Rev1-GFP. These vaccines, in combination with the diagnostic kit that identifies GFP antibodies, can easily distinguish vaccinated animals from infected ones. Meat and milk from a cow infected with brucellosis is unfit for consumption and the fate of these animals ends up being preventative slaughter because the disease is highly contagious and until now it was impossible to solve the DIVA (Differentiation between Infected and Vaccinated Animals) problem.
The only effective solution for the DIVA (Differentiation between Infected and Vaccinated Animals) problem, a large-scale problem and an issue for public health. The vaccination is mandatory in the majority of affected countries (Latin America, Asia, Africa) and all of their governments are demanding an urgent solution to this problem, which is a real headache for health officials. Furthermore, it can achieve savings of up to 50% for countries in the treatment of this disease.